What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

This research investigates the prognostic role of NPM1 in the presence of RAS mutations among older patients with AML.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals RAS mutations negate NPM1's benefit in older AML patients treated with venetoclax and azacitidine.

This research investigates the prognostic role of NPM1 in the presence of RAS mutations among older patients with AML.
Retrospective study of older patients (≥60 years) with newly diagnosed AML treated with VEN+HMA.
Data collected from two cohorts: Beat AML trial and Flatiron Health database.
Mutation analysis performed at diagnosis using next-generation sequencing or PCR.
Overall survival estimated with Kaplan-Meier method.
NPM1 mutations associated with improved survival; RAS mutations negated this benefit.
Median overall survival for patients with NPM1 mutations was higher compared to those without.
In presence of RAS mutations, NPM1's positive prognosis significantly decreased.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark